GO:0031764 type 1 galanin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031764 (type 1 galanin receptor binding) is a molecular function describing the binding of a ligand to the type 1 galanin receptor (GALR1), a G protein-coupled receptor.
• Galanin and its receptor subtypes GALR1 and GALR2 mediate distinct physiological effects, with GALR1 often coupled to Gi/o signaling and GALR2 to Gq/11 signaling.
• Cholesterol modulates the trafficking of GALR1 but not GALR2, highlighting subtype-specific regulation of receptor availability at the cell surface.
• GALR1 activation is implicated in synaptic plasticity, seizure susceptibility, and affective disorders, while GALR2 has roles in cancer and cardiac function.
• Studying type 1 galanin receptor binding requires tools such as radioligand binding assays, knockout mice, and live-cell imaging to dissect ligand-receptor interactions.
• CRISPR-based knockout, knock-in, and overexpression models enable precise interrogation of GALR1 function in health and disease.
Description
Type 1 galanin receptor binding (GO:0031764) is a molecular function that describes the interaction between a ligand and the type 1 galanin receptor (GALR1), a member of the G protein-coupled receptor superfamily. This binding event is the first step in galanin-mediated signaling through GALR1, which is widely expressed in the central and peripheral nervous systems and in some peripheral tissues. The term is used in gene ontology annotations to capture the specific ligand-receptor interaction that initiates downstream cellular responses, distinguishing it from binding to other galanin receptor subtypes such as GALR2. Researchers study this function to understand how galanin and related peptides modulate neuronal excitability, synaptic plasticity, and hormone secretion. The importance of GO:0031764 lies in its role as a molecular entry point for galanin signaling via GALR1. Galanin is a neuropeptide with diverse actions, including regulation of mood, pain, feeding, and seizure threshold. GALR1 activation has been linked to inhibition of adenylyl cyclase and modulation of ion channels, while GALR2 can stimulate phospholipase C. The binding specificity of ligands to GALR1 versus GALR2 is a key determinant of physiological outcome, making this GO term essential for interpreting pharmacological and genetic studies. Dysregulation of galanin signaling has been implicated in conditions such as epilepsy, depression, and cancer. For example, GALR1 knockout mice show altered synaptic plasticity and CREB phosphorylation in the dentate gyrus, suggesting a role in learning and memory. In pancreatic ductal adenocarcinoma, GALR2 rather than GALR1 has been proposed as a target, underscoring the need to distinguish subtype-specific binding. Thus, precise annotation of type 1 galanin receptor binding is critical for both basic neuroscience and translational research.
type 1 galanin receptor binding At A Glance
| GO ID | GO:0031764 |
|---|---|
| GO term | type 1 galanin receptor binding |
| Ontology | molecular_function |
| Synonym | type 1 galanin receptor ligand |
| Major function | Binding of ligands to the type 1 galanin receptor (GALR1), initiating receptor activation and downstream signaling. |
| Receptor subtype | GALR1 (type 1 galanin receptor), a G protein-coupled receptor. |
| Endogenous ligand | Galanin, a 29-30 amino acid neuropeptide. |
| Tissue distribution | Widely expressed in brain, spinal cord, and peripheral tissues including heart and pancreas. |
| Related GO terms | Galanin receptor activity (GO:0004966), type 2 galanin receptor binding (GO:0031765). |
What Is GO:0031764?
Type 1 galanin receptor binding (GO:0031764) is defined as the binding of a ligand to a type 1 galanin receptor (GALR1). This molecular function encompasses the physical interaction between any galanin receptor 1 ligand, such as galanin or synthetic analogs, and the GALR1 protein. It is a subtype-specific binding event, distinct from binding to GALR2 or GALR3, and is the initiating step for GALR1-mediated signal transduction.
Why Is type 1 galanin receptor binding Important in Cell Biology?
Understanding type 1 galanin receptor binding is crucial because it defines the molecular specificity that governs galanin's diverse physiological actions. GALR1 and GALR2 often mediate opposing or distinct effects, and the binding event at GALR1 determines whether signaling proceeds through Gi/o pathways that inhibit cAMP or through other cascades. This specificity is exploited in drug design, where subtype-selective ligands are sought for treating epilepsy, pain, depression, and cancer. Moreover, genetic models such as GALR1 knockout mice have revealed roles in synaptic plasticity and CREB phosphorylation, linking this binding function to memory and emotional regulation. Thus, GO:0031764 serves as a focal point for both mechanistic and therapeutic studies.
• Defines the first step in GALR1-mediated signaling, which regulates neuronal excitability and neurotransmitter release.
• Distinguishes GALR1 from GALR2, enabling subtype-selective drug development.
• Implicated in synaptic plasticity and memory formation through CREB phosphorylation in the dentate gyrus.
• Linked to seizure susceptibility and epilepsy, as GALR1 activation can be anticonvulsant.
• Plays a role in mood disorders, with galanin signaling affecting depression-like behaviors.
• Involved in cardiac function, as galanin receptor 2 (but not type 1) activation reduces atrial fibrillation vulnerability.
• Cholesterol-dependent trafficking of GALR1 affects receptor availability and binding capacity.
• Provides a target for cancer therapy, particularly in tumors where GALR1 expression is altered.
• Essential for interpreting pharmacological studies using galanin analogs and chimeric peptides.
• Enables CRISPR-based functional genomics to dissect GALR1-specific pathways.
Molecular Mechanism of type 1 galanin receptor binding
Ligand Recognition and Binding Pocket
In simple terms: The ligand docks into a specific pocket on the receptor, like a key in a lock.
Type 1 galanin receptor binding begins with the recognition of galanin or a synthetic ligand by the extracellular loops and transmembrane domains of GALR1. The third intracellular loop of GALR1 is important for signal transduction, but ligand binding primarily involves the receptor's N-terminus and extracellular loops. Chimeric galanin-neuropeptide Y peptides have been used to probe the binding specificity, showing that distinct structural features determine whether a ligand activates GALR1 or other receptors. The binding pocket accommodates the conserved N-terminal portion of galanin, which is critical for high-affinity interaction.
Conformational Change and G Protein Coupling
In simple terms: Once the ligand binds, the receptor changes shape and activates a G protein inside the cell.
Ligand binding to GALR1 induces a conformational change that allows the receptor to act as a guanine nucleotide exchange factor for heterotrimeric G proteins, primarily Gi/o. This coupling leads to inhibition of adenylyl cyclase and reduction of cAMP levels, as well as modulation of ion channels. The third intracellular loop of GALR1 is a key determinant of G protein selectivity, and mutations in this region can alter signaling. This step is essential for translating the binding event into cellular responses.
Subtype-Specific Binding and Selectivity
In simple terms: The type 1 receptor is picky about which ligands it binds, unlike the type 2 receptor.
GALR1 and GALR2 share galanin as a ligand but differ in their binding affinities for synthetic analogs and chimeric peptides. For example, the mouse GalR2 receptor has been functionally characterized and shows distinct pharmacological properties compared to GALR1. This subtype specificity is crucial for developing drugs that target only one receptor. The GO term type 1 galanin receptor binding explicitly captures this selectivity, as it refers only to ligands that bind GALR1 and not other galanin receptor subtypes.
Regulation by Membrane Lipids and Trafficking
In simple terms: The receptor's location in the cell membrane is controlled by cholesterol, which affects how much binding can occur.
Cholesterol modulates the trafficking of GALR1 but not GALR2, as shown by live-cell imaging. This means that the availability of GALR1 at the cell surface, and thus its binding capacity, is influenced by membrane lipid composition. Such regulation adds a layer of control to type 1 galanin receptor binding, affecting downstream signaling. This finding also suggests that cholesterol-lowering drugs could indirectly alter GALR1 function.
Downstream Signaling and Cellular Effects
In simple terms: After binding, the receptor triggers a cascade of signals that change cell behavior.
Activation of GALR1 by ligand binding leads to inhibition of cAMP, activation of MAPK pathways, and modulation of ion channels. In the dentate gyrus, GALR1 activation is associated with CREB phosphorylation, a marker of synaptic plasticity. These downstream effects underlie galanin's roles in seizure suppression, mood regulation, and neuroprotection. The specificity of the binding event ensures that these effects are mediated by GALR1 and not other receptors.
Key Genes Involved in GO:0031764 type 1 galanin receptor binding
The following genes and proteins are central to type 1 galanin receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALR1 | Encodes the type 1 galanin receptor, the direct binding target of GO:0031764. | Knockout mice reveal roles in synaptic plasticity and CREB phosphorylation. |
| GAL | Encodes galanin, the endogenous ligand that binds GALR1. | Central to studies of neuropeptide signaling and pain. |
| GALR2 | Encodes the type 2 galanin receptor, a related subtype with distinct binding specificity. | Used to contrast subtype-specific effects and drug selectivity. |
| GALR3 | Encodes the type 3 galanin receptor, another subtype. | Less studied but relevant for understanding receptor family evolution. |
| CREB1 | Transcription factor phosphorylated downstream of GALR1 activation. | Marker of synaptic plasticity in dentate gyrus. |
| GNAI1 | Gi/o alpha subunit coupled to GALR1. | Mediates inhibition of adenylyl cyclase upon GALR1 binding. |
| GNAI2 | Another Gi alpha subunit potentially coupled to GALR1. | Contributes to GALR1 signaling diversity. |
| GNAQ | Gq alpha subunit often coupled to GALR2, not GALR1. | Used to differentiate GALR1 vs GALR2 signaling. |
| ADCY1 | Adenylyl cyclase inhibited by GALR1 activation. | Readout for GALR1-mediated cAMP reduction. |
| MAPK1 | ERK2, activated downstream of GALR1 in some contexts. | Links GALR1 binding to proliferation and differentiation. |
| MAPK3 | ERK1, similar to MAPK1. | Potential mediator of GALR1 effects on gene expression. |
| NPY | Neuropeptide Y, used in chimeric peptides to probe galanin receptor binding. | Helps define ligand specificity for GALR1. |
| SPX | Spexin, a peptide that acts on galanin receptors. | Shown to reduce atrial fibrillation via GALR2, highlighting subtype selectivity. |
| CHRM1 | Muscarinic receptor, not directly related but used in comparative studies. | Context for G protein-coupled receptor signaling. |
| SLC2A4 | GLUT4, downstream of metabolic effects of galanin. | Links GALR1 to glucose uptake in peripheral tissues. |
| POMC | Pro-opiomelanocortin, modulated by galanin signaling. | Relevant to feeding and energy balance. |
| TAC1 | Substance P precursor, co-expressed with galanin in sensory neurons. | Implicated in pain pathways involving GALR1. |
| BDNF | Brain-derived neurotrophic factor, influenced by galanin signaling. | Linked to synaptic plasticity and depression. |
How Is type 1 galanin receptor binding Regulated?
Type 1 galanin receptor binding is regulated at multiple levels. Receptor availability at the cell surface is modulated by cholesterol, which affects GALR1 trafficking but not GALR2. Ligand concentration in the extracellular space is controlled by galanin synthesis, release, and degradation. Additionally, receptor desensitization and internalization following prolonged agonist exposure can reduce binding capacity. The third intracellular loop of GALR1 influences signal transduction efficiency, indirectly affecting the functional consequences of binding. These regulatory mechanisms ensure that GALR1 signaling is tightly controlled in vivo.
type 1 galanin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALR1 | Epilepsy, depression, synaptic plasticity | GALR1 knockout mice, CRISPR KO in neuronal cell lines. |
| GAL | Pain, feeding, mood disorders | Galanin overexpression or knockout models. |
| GALR2 | Pancreatic ductal adenocarcinoma, atrial fibrillation | GALR2 knockout or overexpression in cancer cell lines. |
| CREB1 | Memory, synaptic plasticity | CREB phosphorylation assays in GALR1 KO mice. |
| SPX | Cardiac arrhythmia | Spexin treatment in atrial fibrillation models. |
Epilepsy and Seizure Susceptibility
Galanin signaling through GALR1 has anticonvulsant effects in several seizure models. GALR1 knockout mice exhibit altered synaptic plasticity and CREB phosphorylation in the dentate gyrus, suggesting that loss of type 1 galanin receptor binding impairs neuronal adaptation and may increase seizure susceptibility. This makes GALR1 a potential target for antiepileptic drugs that enhance galanin binding.
Depression and Mood Disorders
Galanin and its receptors are implicated in depression-like behaviors. GALR1 activation can modulate serotonergic and noradrenergic systems, and changes in GALR1 binding may contribute to mood dysregulation. Studies using GALR1 knockout mice have shown altered stress responses, supporting a role for type 1 galanin receptor binding in affective disorders.
Cancer
Galanin receptors are expressed in various cancers. While GALR2 has been proposed as a target in pancreatic ductal adenocarcinoma, GALR1 expression is also altered in some tumors. The binding of ligands to GALR1 can influence proliferation and apoptosis, making it a potential therapeutic target. However, subtype specificity is critical, as GALR1 and GALR2 may have opposing effects.
Cardiac Arrhythmias
Spexin, a peptide ligand for galanin receptors, reduces atrial fibrillation vulnerability by acting on GALR2, not GALR1. This highlights the importance of subtype-specific binding: type 1 galanin receptor binding may have different cardiac effects, and understanding this distinction is essential for developing safe therapeutics.
From type 1 galanin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GALR1 mediate specific galanin effects in vivo? | GALR1 knockout mouse. |
| How does cholesterol affect GALR1 binding? | Live-cell imaging with cholesterol depletion in GALR1-expressing cells. |
| What is the role of GALR1 in cancer? | CRISPR knockout of GALR1 in pancreatic cancer cell lines. |
| Can subtype-selective ligands be developed? | Point mutations in GALR1 binding pocket, knock-in mice. |
| How does GALR1 trafficking influence signaling? | Tagged knock-in of GALR1 with fluorescent protein. |
| What are the downstream targets of GALR1 activation? | Overexpression of GALR1 followed by RNA-seq. |
How to Study the type 1 galanin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and density of GALR1 binding sites | Characterizing subtype-selective ligands. |
| Live-cell imaging | Receptor trafficking and localization | Cholesterol effects on GALR1. |
| cAMP assay | Gi/o-mediated inhibition of adenylyl cyclase | Functional readout of GALR1 activation. |
| CREB phosphorylation | Downstream synaptic plasticity signaling | GALR1 knockout studies in dentate gyrus. |
| CRISPR knockout | Loss-of-function of GALR1 | Cancer cell proliferation studies. |
| RNA-seq | Transcriptional changes after GALR1 activation | Identifying downstream targets. |
| Immunohistochemistry | Tissue distribution of GALR1 protein | Mapping expression in brain and periphery. |
| Patch-clamp electrophysiology | Ion channel modulation by GALR1 | Neuronal excitability studies. |
Radioligand Binding Assays
Radioligand binding assays using iodinated galanin or synthetic analogs are the gold standard for measuring type 1 galanin receptor binding affinity and density. These assays can distinguish GALR1 from GALR2 by using subtype-selective ligands or membrane preparations from cells expressing only one receptor.
Live-Cell Imaging
Live-cell imaging with fluorescently tagged GALR1 allows real-time visualization of receptor trafficking and binding in response to ligands and cholesterol modulation. This method reveals dynamic changes in receptor localization that affect binding capacity.
Genetic Knockout and Knock-in Models
GALR1 knockout mice have been instrumental in linking type 1 galanin receptor binding to synaptic plasticity and CREB phosphorylation. CRISPR-Cas9 can generate knockout cell lines and knock-in reporters to study binding in vitro.
Downstream Signaling Assays
cAMP inhibition assays, MAPK phosphorylation, and CREB activation are used to measure functional consequences of GALR1 binding. These readouts confirm that ligand binding translates into biological effects.
How CRISPR Can Be Used to Study GO:0031764 type 1 galanin receptor binding
Knockout
CRISPR-Cas9 knockout of GALR1 eliminates type 1 galanin receptor binding, allowing researchers to attribute specific galanin effects to this receptor subtype. For example, GALR1 knockout mice show altered CREB phosphorylation in the dentate gyrus, confirming a role in synaptic plasticity. In cancer cell lines, GALR1 knockout can reveal whether galanin-mediated growth inhibition depends on this receptor.
Point Mutation
Point mutations in the GALR1 gene can be introduced to dissect the binding pocket or third intracellular loop, which is critical for signal transduction. Such mutations help identify residues essential for ligand binding versus G protein coupling, refining the molecular understanding of GO:0031764.
Knock-in
Knock-in of fluorescent or epitope tags into the endogenous GALR1 locus enables real-time tracking of receptor trafficking and binding in live cells. This approach preserves native expression levels and regulatory elements, providing physiologically relevant insights into type 1 galanin receptor binding.
Overexpression
Overexpression of GALR1 in cell lines increases the number of binding sites, facilitating biochemical assays and drug screening. This can be achieved by CRISPR-mediated knock-in of a strong promoter or by lentiviral transduction. Overexpression models are useful for studying downstream signaling and identifying novel ligands.
How EDITGENE Supports type 1 galanin receptor binding Research
Researchers studying type 1 galanin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous interrogation of GO:0031764 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for type 1 galanin receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GAL Knockout HEK293T Cell Line | EDJ-KQ97 | Human | 51083 | Details Get a Quote |
| GAL Knockout HEK293 Cell Line | EDJ-KQ2048 | Human | 51083 | Details Get a Quote |
| GAL Knockout HCT 116 Cell Line | EDJ-KQ17932 | Human | 51083 | Details Get a Quote |
| GAL Knockout A-549 Cell Line | EDJ-KQ23469 | Human | 51083 | Details Get a Quote |
| GAL Knockout HeLa Cell Line | EDJ-KQ23471 | Human | 51083 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
Frequently Asked Questions About type 1 galanin receptor binding
What is type 1 galanin receptor binding?
Type 1 galanin receptor binding (GO:0031764) is the molecular function of a ligand, such as galanin, binding to the type 1 galanin receptor (GALR1), initiating downstream signaling.
What genes are involved in type 1 galanin receptor binding?
The primary gene is GALR1, which encodes the receptor. The ligand galanin is encoded by GAL. Other related genes include GALR2 and GALR3.
What is the difference between GALR1 and GALR2 binding?
GALR1 and GALR2 are distinct receptor subtypes with different ligand affinities and signaling pathways. GALR1 is often coupled to Gi/o, while GALR2 can couple to Gq/11.
How is type 1 galanin receptor binding studied?
Common methods include radioligand binding assays, live-cell imaging, cAMP assays, and CRISPR knockout models.
What diseases are associated with type 1 galanin receptor binding?
It has been implicated in epilepsy, depression, cancer, and cardiac arrhythmias, though some effects are subtype-specific.
Does cholesterol affect type 1 galanin receptor binding?
Yes, cholesterol modulates the trafficking of GALR1 but not GALR2, which can influence receptor availability at the cell surface.
Can CRISPR be used to study type 1 galanin receptor binding?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect GALR1 function and binding.
What is the role of the third intracellular loop in GALR1?
The third intracellular loop of GALR1 is important for signal transduction and G protein coupling, affecting the consequences of ligand binding.
Are there subtype-selective ligands for GALR1?
Yes, chimeric galanin-neuropeptide Y peptides and other synthetic analogs have been used to probe subtype selectivity.
What is the clinical relevance of type 1 galanin receptor binding?
It is a potential drug target for neurological and psychiatric disorders, as well as cancer, but subtype specificity must be considered.
Conclusion
Type 1 galanin receptor binding (GO:0031764) is a fundamental molecular function that governs the initial step of GALR1-mediated signaling. Its specificity distinguishes GALR1 from other galanin receptor subtypes and underlies diverse physiological roles in the nervous system, heart, and periphery. Dysregulation of this binding event has been linked to epilepsy, mood disorders, and cancer, making it a compelling target for therapeutic development. Advances in CRISPR-based genome editing and live-cell imaging continue to refine our understanding of GALR1 trafficking, ligand selectivity, and downstream signaling. By leveraging these tools, researchers can dissect the precise contributions of type 1 galanin receptor binding to health and disease, ultimately guiding the design of subtype-selective drugs.
References
- 1. Li D et al.. 2024. Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2.. Circulation 150(2):111-127 PMID: 38726666
- 2. Li T et al.. 2026. Cholesterol modulates trafficking of galanin receptor subtype 1 but not subtype 2: Insights from live-cell imaging.. Br J Pharmacol 183(3):453-471 PMID: 40968027
- 3. Kahl U et al.. 1994. Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.. Br J Pharmacol 111(4):1129-34 PMID: 7518295
- 4. Badie-Mahdavi H et al.. 2005. Role of galanin receptor 1 and galanin receptor 2 activation in synaptic plasticity associated with 3',5'-cyclic AMP response element-binding protein phosphorylation in the dentate gyrus: studies with a galanin receptor 2 agonist and galanin receptor 1 knockout mice.. Neuroscience 133(2):591-604 PMID: 15885916
- 5. Rezaei K et al.. 2000. Role of third intracellular loop of galanin receptor type 1 in signal transduction.. Neuropeptides 34(1):25-31 PMID: 10688965
- 6. Namsolleck P et al.. 2023. Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma.. Int J Mol Sci 24(12) PMID: 37373336
- 7. Oláh J et al.. 2026. Galanin Receptors: G Protein-Dependent Signaling and Beyond.. Biomolecules 16(2) PMID: 41750307
- 8. Pang L et al.. 1998. The mouse GalR2 galanin receptor: genomic organization, cDNA cloning, and functional characterization.. J Neurochem 71(6):2252-9 PMID: 9832122
